| Number: HOG QL12-153 |
Principal Investigator: Picus, Joel |
| Title: Phase II study of Fosaprepitant + 5HT3 receptor antagonists + Dexamethasone in patients with germ cell tumors undergoing 5 day Cisplatin based chemotherapy |
| Description: The purpose of this study is to determine if EMEND can reduce sudden and delayed symptoms of nausea and vomiting in patients with germ cell cancer that are receiving standard
treatment with a 5-day Cisplatin-based chemotherapy....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201108327 |
Principal Investigator: Wang-Gillam, Andrea |
| Title: Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies |
| Description: The purpose of this study is to determine the maximum tolerated dose and side effects of the combination of two drugs, temsirolimus and erlotinib, used to treat solid tumor cancers. Temsirolimus is approved by the Food and Drug Administration (FDA) for treatment of renal cancer and is considered inv...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201107068 |
Principal Investigator: Lockhart, A. Craig |
| Title: Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients with Varying Degrees of Hepatic Impairment |
| Description: The purpose of this study is to determine if Cabazitaxel is a safe treatment for patients with advanced cancers of different types who also have different levels of liver dysfunction. The highest safe dose of cabazitaxel (the maximum tolerated dose, or MTD) that can be given to patients with your le...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201102462 |
Principal Investigator: Lockhart, A. Craig |
| Title: A Phase 1b, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Daily Oral Doses of ZSTK474 in Subjects with Advanced Solid Malignancies |
| Description: The main purpose of this study is to find out if the drug ZSTK474 is safe in people who have advanced cancers.
ZSTK474 is an investigational (experimental) drug. This means it has not been approved by the Food and Drug Administration (FDA). It is not currently on the market in any country. This stu...MORE |
| ___________________________________________________________________________________________________ |